Trial Profile
A Phase 1/2a Open Label Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs PGDM1400 (Primary) ; PGT 121 (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- 06 Mar 2024 Results assessing therapeutic efficacy of a triple combination of HIV-1 broadly neutralizing antibodies, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 Mar 2024 Results (n=12) presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
- 06 May 2022 Status changed from recruiting to completed.